Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer

Table 3

Patient demographics and clinical characteristics for those who received GC or MVAC neoadjuvant chemotherapy.

	GC; 𝑁 (%)	MVAC; 𝑁 (%)	𝑃 value
Gender			0.10
Male	31 (76%)	28 (90%)
Female	10 (24%)	3 (10%)
Age			0.01
<60	13 (31%)	14 (45%)
60–69	14 (34%)	16 (51%)
>70	14 (34%)	1 (3%)
Race			0.47
Caucasian	35 (85%)	29 (94%)
Other	6 (15%)	2 (6%)
Complete TURBT			0.72
Yes	16 (41%)	14 (45%)
No	22 (59%)	15 (55%)
Cardiac disease			0.25
Yes	8 (20%)	3 (10%)
No	33 (80%)	28 (90%)
Creatinine			0.24
≤1.0	28 (68%)	17 (53%)
>1.0	13 (32%)	14 (47%)
Clinical T-stage			0.52
T2	23 (56%)	14 (45%)
T3	11 (27%)	9 (29%)
T4	7 (17%)	8 (26%)
Pathologic T-stage			0.45
pT0	12 (29%)	7 (23%)
pTa	0 (0%)	2 (6%)
pTIS	8 (20%)	2 (6%)
pT1	3 (7%)	3 (10%)
pT2	4 (10%)	6 (20%)
pT3a	8 (20%)	6 (20%)
pT3b	2 (5%)	2 (7%)
pT4	4 (10%)	2 (7%)
Pathologic N-stage			0.09
N0	35 (85%)	22 (71%)
N1	6 (15%)	9 (28%)